213 completed, 86 terminated, 44 unknown, 42 recruiting. 258 Phase 2, 217 Phase 1, 23 Phase 3, 15 Not applicable, 11 Early Phase 1.
Follow Interleukin-2: new trials by email Literature Review of Interleukin-2 trials Research Report on Interleukin-2
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Locoregional Administration of TIL and Lymphodepletion in Patients With Melanoma and Liver Metastases Autologous Tumor Infiltrating Lymphocytes, Melphalan, Interleukin-2 - Uveal Melanoma, Metastatic Cutaneous Melanoma | Phase 1 | Not yet recruiting | Vastra Gotaland Region | 6 | 2027-01-31 | 2026-09-09 |
| Locoregional or Systemic Administration of Autologous Tumor Infiltrating Lymphocytes in Patients With Metastatic Melanoma Autologous Tumor Infiltrating Lymphocytes (TIL), Melphalan, Interleukin-2 - Metastatic Uveal Melanoma, Metastatic Cutaneous Melanoma | Phase 1 | Not yet recruiting | Vastra Gotaland Region | 18 | 2027-01-01 | 2026-09-09 |
| Autologous Tumor Infiltrating Lymphocyte (TIL) GT201 Infusion. GT201, IL-2 and PD-1 - Advanced Solid Tumors Cancer | Phase 1 / Phase 2 | Not yet recruiting | Gritbio Medicine, Inc. | 63 | 2026-11-01 | 2026-08-14 |
| PICSTAT Pilot Study for CD8 PET/CT-Guided Lifileucel Treatment in Advanced Melanoma Resection of PET (high) and PET (low) Tumors, Lifileucel Manufacturing Clinical v Research, Chemotherapy Regimen - Unresectable or Metastatic Melanoma | Early Phase 1 | Not yet recruiting | Abramson Cancer Center at Penn Medicine | 10 | 2026-10-01 | 2026-07-13 |
| A Study Evaluating the Immunotherapy Treatment for Ovarian Cancer and Other Advanced Malignancies. Decitabine, Cyclophosphamide Conditioning, NY-ESO-1 TCR/ dnTGFβRII - Ovarian Cancer, Advanced Malignant Solid Tumor | Phase 1 / Phase 2 | Recruiting | University of Chicago | 24 | 2026-09-09 | 2026-10-13 |
| Study Evaluating a Gene Therapy for IPEX Syndrome Through the Expression of FOXP3 on Deficient T Cells to Produce Tregs-like. FOXP3-T4 drug product, ILT-101 - The Immune Dysregulation Polyendocrinopathy Enteropathy X-linked Syndrome is a Primary Immunodeficiency Caused by Pathogenic Variants in Forkhead Box Protein 3 | Phase 1 / Phase 2 | Not yet recruiting | Assistance Publique - Hôpitaux de Paris | 5 | 2026-09-01 | 2026-07-13 |
| Interleukine-2 (IL-2) Plus Semaglutide in Alzheimer's Disease IL-2 (Aldesleukin), Semaglutide Plus IL-2, Placebo - Alzheimer Dementia (AD) | Phase 1 / Phase 2 | Recruiting | The Methodist Hospital Research Institute | 30 | 2026-09-01 | 2026-09-23 |
| Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL) Allogeneic NK cells, Rituximab, Tafasitamab - Non Hodgkin Lymphoma, B-cell Non Hodgkin Lymphoma | Phase 1 | Recruiting | Paolo Caimi, MD | 15 | 2026-09-01 | 2026-09-09 |
| Efficacy and Safety of Low-Dose IL-2 in Neuromyelitis Optica Spectrum Disorder Placebo, IL-2 (interleukin 2) - Neuromyelitis Optica Spectrum Disorder (NMOSD) | Phase 2 | Not yet recruiting | Peking University People's Hospital | 60 | 2026-08-30 | 2026-09-09 |
| HS-IT101 Injection for Advanced NSCLC(FASTIL-Lung01) Cyclophosphamide, Fludarabine, IL-2 (interleukin 2) - Advanced Non-Small Cell Lung Cancer | Phase 1 | Recruiting | Hangzhou Huasai Biomedicine Co., Ltd. | 12 | 2026-08-30 | 2026-10-14 |
| A Phase II Trial of Tumour Infiltrating Lymphocyte Adoptive Cell Therapy in Patients With Immune Checkpoint Inhibitor Resistant Unresectable or Metastatic Melanoma Tumour Infiltrating Lymphocytes Adoptive Cell Therapy, Cyclophosphamide + Fludarabine Lymphodepletive Conditioning, Aldesleukin - Melanoma (Skin Cancer), Melanoma Metastatic | Phase 2 | Not yet recruiting | East Metropolitan Health Service, Australia | 10 | 2026-07-01 | 2026-06-16 |
| IDP-023 g-NK Cells Plus Ocrelizumab in Patients With Progressive Multiple Sclerosis IDP-023, Ocrelizumab, Interleukin-2 - Multiple Sclerosis, Primary Progressive Multiple Sclerosis (PPMS) | Phase 1 | Suspended | Indapta Therapeutics, INC. | 34 | 2026-06-30 | 2025-04-30 |
| Fast TILs to Treat Metastatic Cancer Patients With Pleural Disease locally manufactured adoptive cellular therapy (ACT) product, Interleukin-2 - Malignant Pleural Effusion, Malignant Mesothelioma | Phase 1 | Recruiting | David Bartlett, MD | 10 | 2026-06-03 | 2026-08-04 |
| Adapt NK for High Risk Myeloid Diseases as Bridge to Allo HSCT AdaptNK, Fludarabine, Cyclophosphamide - Relapsed Adult AML, Refractory AML | Phase 1 / Phase 2 | Recruiting | Masonic Cancer Center, University of Minnesota | 18 | 2026-05-08 | 2026-05-19 |
| Fast TILs to Treat Metastatic Pleural Effusions From Epithelial or Mesothelial Primary Tumors locally manufactured adoptive cellular therapy (ACT) product, Interleukin-2 (IL-2) - Malignant Pleural Effusion, Malignant Mesothelioma | Phase 1 | Recruiting | Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute) | 10 | 2026-05-01 | 2026-04-07 |
| TIL Therapy in cSCC and MCC LN-145, Cyclophosphamide, Fludarabine - Cutaneous Squamous Cell Carcinoma, Merkel Cell Carcinoma | Phase 2 | Recruiting | Karam Khaddour, MD, MS | 14 | 2026-02-10 | 2026-02-13 |
| Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors EB-SELECT Single-Target CAR-NK Cells, Dual-Target Antigen-Selected CAR-NK - Cancer, Breast Cancer | Phase 1 / Phase 2 | Recruiting | Essen Biotech | 85 | 2026-02-01 | 2026-02-18 |
| Efficacy of Interleukin-2 in Triple Negative Breast Cancer Human Interleukin-2 (IL-2) (Proleukin) - Triple Negative Breast Cancer | Phase 1 / Phase 2 | Not yet recruiting | Nova Scotia Health Authority | 10 | 2026-01-02 | 2025-02-12 |
| Clinical Trial of CD40L-augmented TIL for Patients With Advanced Melanoma Cyclophosphamide, Fludarabine, Interleukin-2 - Melanoma | Phase 1 / Phase 2 | Recruiting | H. Lee Moffitt Cancer Center and Research Institute | 36 | 2025-12-03 | 2026-06-26 |
| A FIH, Phase I/IIa, Trial Assessing Feasibility of Administrations of TIL-based Immunotherapy in Patients With Metastatic CRC and PC CC-38, Pembrolizumab, Cyclophosphamid - Metastatic Colorectal Cancer, Prostate Cancer Metastatic | Phase 1 / Phase 2 | Recruiting | CuraCell TX AB | 12 | 2025-11-13 | 2026-06-22 |
Showing 20 of 446. Sign in to see all of them.
Melanoma (107) · Carcinoma, Renal Cell (38) · Leukemia, Myeloid, Acute (36) · Neoplasm Metastasis (31) · HIV Infections (24) · Breast Neoplasms (22) · Neoplasms (22) · Lymphoma, Non-Hodgkin (21) · Kidney Neoplasms (20) · Carcinoma, Non-Small-Cell Lung (18) · Leukemia (18) · Neuroblastoma (17) · Skin Neoplasms (17) · Colorectal Neoplasms (16) · Ovarian Neoplasms (16)
National Cancer Institute (NCI) (46) · Masonic Cancer Center, University of Minnesota (22) · H. Lee Moffitt Cancer Center and Research Institute (18) · Peking University People's Hospital (17) · M.D. Anderson Cancer Center (16) · National Institute of Allergy and Infectious Diseases (NIAID) (16) · Fred Hutchinson Cancer Center (11) · Dana-Farber Cancer Institute (10) · St. Jude Children's Research Hospital (10) · Inge Marie Svane (8) · Assistance Publique - Hôpitaux de Paris (7) · Essen Biotech (6) · Fate Therapeutics (5) · Second Affiliated Hospital of Soochow University (5) · The Methodist Hospital Research Institute (5)
United States (269) · China (59) · France (27) · Denmark (15) · United Kingdom (15) · Spain (14) · Italy (12) · Australia (9) · Germany (9) · Canada (8) · Switzerland (8) · Netherlands (7) · Israel (6) · Portugal (5) · Sweden (5)
Steven A Rosenberg, M.D. (8) · Zhanguo Li (8) · Amod Sarnaik, M.D. (4) · Erwei Song, M.D., Ph.D. (4) · Steven Rosenberg, M.D. (4) · Cassian Yee (3) · George Coukos, MD, PhD (3) · James Yang, M.D. (3) · Jeffrey Miller, MD (3) · Marcus Butler, M.D. (3) · Rodabe N. Amaria, MD (3) · Amanda Cashen, M.D. (2) · Arie Belldegrun, MD, FACS (2) · Bohdan Pomahac, MD (2)
PMID 22555974, PMID 23861247, PMID 27641687, PMID 32747469, PMID 24719405, PMID 30573690, PMID 33986124, PMID 34385708, PMID 35537408, PMID 37146227, PMID 11359672, PMID 12473581, PMID 12810695, PMID 14581425, PMID 15206062, PMID 16710345, PMID 16947019, PMID 16982775, PMID 17919105, PMID 18157014, PMID 18256325, PMID 19010868, PMID 19097774, PMID 19128501, PMID 19304957, PMID 19430405, PMID 19461505, PMID 19508157, PMID 19622576, PMID 19828532, PMID 20056794, PMID 20085940, PMID 20124177, PMID 20186278, PMID 20413658, PMID 20522709, PMID 20567002, PMID 20668228, PMID 20812949, PMID 21631324, PMID 21632855, PMID 22129252, PMID 22160384, PMID 22308288, PMID 22353759, PMID 22426890, PMID 22721971, PMID 22909342, PMID 22911697, PMID 23014345
2015 (4), 2019 (4), 2023 (3), K12CA076930 (3), 2004 (2), 2014 (2), 2018 (2), 2025 (2), P01CA018029 (2), P30CA022453 (2), P30CA023108 (2), R01CA095648 (2), U10CA031946 (2), U10CA032102 (2), 2008 (1)